Sign In
Buy RGEN
$149.78
+2.72 (+1.85%)
At Close: Aug 04, 2026
Repligen (RGEN) Beats on Q2 Earnings, Lowers '23 Guidance
12:45pm, Thursday, 03'rd Aug 2023
Repligen's (RGEN) second-quarter earnings and revenues beat their respective Zacks Consensus Estimate. Chromatography and process analytics businesses are the key growth drivers in the quarter.
Repligen Corporation (RGEN) Q2 2023 Earnings Call Transcript
03:26pm, Wednesday, 02'nd Aug 2023
Repligen Corporation (NASDAQ:RGEN ) Q2 2023 Earnings Conference Call August 2, 2023 8:30 AM ET Company Participants Sondra Newman - Global Head of Investor Relations Tony Hunt - President and Chief Ex
Repligen (RGEN) Q2 Earnings Surpass Estimates
10:27am, Wednesday, 02'nd Aug 2023
Repligen (RGEN) came out with quarterly earnings of $0.53 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $0.91 per share a year ago.
EXEL or RGEN: Which Is the Better Value Stock Right Now?
01:08pm, Tuesday, 25'th Jul 2023
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Exelixis (EXEL) and Repligen (RGEN). But which of these two stocks presents investors wi
Repligen: The Hidden Gem In Single-Use Solutions For Biopharma Manufacturing
11:35am, Tuesday, 18'th Jul 2023
Repligen, a leading company in biological drug manufacturing, has seen significant growth with sales increasing from $141 million in FY17 to $802 million in FY22, largely due to their single-use produ
Repligen Corporation: Not Able To Replicate The Strong Results
12:11pm, Monday, 05'th Jun 2023
Repligen Corporation is facing tougher comparables with the pandemic-related revenue contribution vanishing. This is expected, but the softer organic growth in the base business is disappointing. With
Repligen (RGEN) Beats on Q1 Earnings, Lowers 2023 Guidance
02:27pm, Wednesday, 03'rd May 2023
Repligen's (RGEN) first-quarter earnings and revenues beat estimates.
Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates
10:40am, Tuesday, 02'nd May 2023
Repligen (RGEN) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.59 per share. This compares to earnings of $0.92 per share a year ago.
Why Repligen Stock Is Sinking Today
02:07pm, Tuesday, 25'th Apr 2023
Repligen is set to release its first-quarter earnings next Tuesday. Demand for its COVID-related products is declining, and investors appear to be bracing for the company to miss Wall Street's consens
Repligen to Report First Quarter 2023 Financial Results
07:30am, Tuesday, 18'th Apr 2023
Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET Webcast and Conference Call to Be Held Tuesday, May 2, 2023, at 8:30 a.m. ET
Why Is Repligen (RGEN) Down 11.4% Since Last Earnings Report?
12:59pm, Friday, 24'th Mar 2023
Repligen (RGEN) reported earnings 30 days ago. What's next for the stock?
Repligen Corporation to Present at KeyBanc Life Science and MedTech Investor Forum
07:30am, Tuesday, 14'th Mar 2023
WALTHAM, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will present virt
Repligen: Exclusive Partnerships And Innovation Set To Drive Growth
10:23am, Sunday, 12'th Mar 2023
Repligen's exclusive partnerships with companies such as DRS Daylight Solutions and Purolite give it a competitive edge in the industry. The company's diverse product line includes pre-packed columns,
Repligen's (RGEN) Q4 Earnings and Revenues Beat Estimates
03:03pm, Thursday, 23'rd Feb 2023
Repligen (RGEN) reports encouraging fourth-quarter and full-year 2022 results, with sales and earnings beating estimates.
Repligen Corporation (RGEN) Q4 2022 Earnings Call Transcript
02:38pm, Wednesday, 22'nd Feb 2023
Start Time: 08:30 January 1, 0000 9:37 AM ET Repligen Corporation (NASDAQ:RGEN ) Q4 2022 Earnings Conference Call February 22, 2023, 08:30 AM ET Company Participants Tony Hunt - President and CEO Jon
